Charles O’Brien Receives Institute of Medicine's 2010 Sarnat Prize in Mental Health
The Institute of Medicine today awarded the 2010 Rhoda and Bernard Sarnat International Prize in Mental Health to two scientists — Charles P. O'Brien, MD, PhD, the Kenneth Appel Professor of Psychiatry and vice chair of psychiatry at the University of Pennsylvania School of Medicine; and Eric J. Nestler, MD, PhD, the Nash Family Professor of Neuroscience, chair of the department of neuroscience, and director of the Friedman Brain Institute at Mount Sinai School of Medicine — for their complementary achievements in addiction science. The Sarnat Prize, consisting of a medal and $20,000, recognizes the researchers' leading roles in elucidating the biological mechanics of addiction, improving the quality of care offered by treatment programs, and ultimately reducing the stigma associated with the condition. The prize was presented to O'Brien and Nestler at IOM's annual meeting in Washington, D.C.
When the Schuylkill swallowed the city: Lessons from Hurricane Ida’s historic flood
New Penn research shows that Hurricane Ida wasn’t a once-in-a-century anomaly but a preview of how climate change, urbanization, and aging infrastructure are rewriting flood risk.
The Fed explained: What it does and why it matters
Former Philadelphia Fed President Patrick Harker and financial historian Peter Conti-Brown, both Wharton professors, unpack the central bank’s origins, its unusual structure, and the quiet ways it shapes the economy
How population changes are impacting primary education worldwide
Research from Penn sociologist Emily Hannum and colleagues reveals regional trends in whether school-age populations are increasing, plateauing, or decreasing—and shows how different countries are responding.
A bioengineered bean gum from the lab of Penn Dental’s Henry Daniell is found to reduce the levels of three microbes associated with head and neck squamous cell cancer to almost zero, without affecting the beneficial bacteria normally found in the mouth.
Fighting oral cancer with bioengineered chewing gum
Research led by Penn Dental’s Henry Daniell shows that antiviral and antibacterial chewing gums reduce the levels of three microbes linked to worse outcomes in oral cancers, paving the way for more effective and affordable therapies.
